Malawi has been certified to start administering the Lenacapavir medicine used for HIV prevention.
Lenacapavir is administered as a six-monthly injection just under the skin, to individuals who are HIV negative and at substantial risk of HIV infection.
This is according to a statement co-signed by Pharmacy Medicines and Regulatory Authority PMRA and National Aids Commission (NAC).
PMRA’s Director General, Mphatso Kawaye said registration of Lenacapavir in Malawi marks a major breakthrough in HIV prevention.
Kawaye adds that this shows unwavering commitment to fast-tracking access to high-quality, safe and effective medicines, leveraging reliance-based approach.
NAC Chief Executive Officer, Dr. Beatrice Matanje, says its twice-yearly administration significantly reduces dosing burden and minimizes frequency of healthcare facility visits, thereby improving patient convenience and supporting long-term adherence.
About The Author
